IAM
KERX

Iridian Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Iridian Asset Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-220,600
Closed -$1.59M – 88
2017
Q2 		$1.59M Sell
220,600
-44,510
-17% -$278K 0.01% 66
2017
Q1 		$1.63M Buy
265,110
+36,540
+16% +$200K 0.01% 65
2016
Q4 		$1.34M Buy
+228,570
New +$1.25M 0.01% 65

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Iridian Asset Management's KERX Position: Q3 2017 in Review

Iridian Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2017, closing a stake of 220,600 shares — an estimated $1.59M sold.

Iridian Asset Management first reported a position in KERX in Q4 2016 and held it in 3 quarters. The position peaked at $1.63M in Q1 2017. 132 funds tracked by Wall St. Rank hold KERX as of Q3 2017.

  • Iridian Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Iridian Asset Management sold 220,600 Keryx Biopharmaceuticals Inc shares in Q3 2017, an estimated $1.59M.
  • Iridian Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q4 2016 and held it in 3 quarters.
  • Iridian Asset Management's Keryx Biopharmaceuticals Inc position peaked at $1.63M in Q1 2017.
  • 132 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2017.

Based on Iridian Asset Management's 13F filing for Q3 2017, filed 8 Nov 2017.